Keytruda

Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review
Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA review
Pharmaforum
Merck
Keytruda
FDA
colorectal cancer
Flag link:
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Flag link:
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Fierce Pharma
Merck
Keytruda
FDA
squamous cell carcinoma
Sanofi
Regeneron
Libtayo
Flag link:
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Endpoints
Merck
Keytruda
Bristol-Myers Squibb
FDA
biomarkers
accelerated approvals
cancer
TMB
Flag link:
Merck & Co’s Keytruda fails in first line bladder cancer
Merck & Co’s Keytruda fails in first line bladder cancer
Pharmaforum
Merck
Keytruda
bladder cancer
Flag link:
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
Flag link:
ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients
ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients
Fierce Pharma
Merck
Keytruda
clinical trials
ASCO 2020
colorectal cancer
Flag link:
ASCO 2020 – first-line lung cancer focus
ASCO 2020 – first-line lung cancer focus
EP Vantage
Roche
Merck
Bristol-Myers Squibb
ASCO 2020
lung cancer
Keytruda
tiragolumab
Opdivo
Yervoy
Flag link:
ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no
ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no
Fierce Pharma
ASCO 2020
Merck
Keytruda
extensive-stage small cell lung cancer
Flag link:
Merck grabs FDA green light for less-frequent Keytruda dosing regimen
Merck grabs FDA green light for less-frequent Keytruda dosing regimen
Fierce Pharma
Merck
FDA
Keytruda
Flag link:
Merck builds case for six-week Keytruda dosing as FDA starts review
Merck builds case for six-week Keytruda dosing as FDA starts review
Pharmaforum
Merck
Keytruda
AACR
FDA
Flag link:
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck
BioSpace
Rexahn
triple negative breast cancer
Merck
Keytruda
Flag link:
FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ use
FDA reviews Merck & Co’s Keytruda in new ‘tumour agnostic’ use
Pharmaforum
Merck
Keytruda
tumor agnostic drugs
biomarkers
Flag link:
Seattle Genetics Issue Update on Padcev Label Expansion Study
Seattle Genetics Issue Update on Padcev Label Expansion Study
Yahoo/Zacks.com
Seattle Genetics
Padcev
Merck
Keytruda
urothelial cancer
Flag link:
Merck scores new advance on tumor-agnostic front as Keytruda beat chemo-based regimens in a type of colorectal cancer
Merck scores new advance on tumor-agnostic front as Keytruda beat chemo-based regimens in a type of colorectal cancer
Endpoints
Merck
Keytruda
colorectal cancer
Flag link:
FDA Rejects Merck's 6-Week Dosing Schedule for Keytruda
FDA Rejects Merck's 6-Week Dosing Schedule for Keytruda
BioSpace
Merck
Keytruda
FDA
Flag link:
Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
Endpoints
Merck
Keytruda
triple negative breast cancer
clinical trials
Roche
Flag link:
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BioSpace
BeiGene
tiselizumab
non-small cell lung cancer
Merck
Keytruda
Flag link:
Merck's Blockbuster Drug Wins Key New FDA Approval
Merck's Blockbuster Drug Wins Key New FDA Approval
Motley Fool
Merck
Keytruda
bladder cancer
NMIBC
Flag link:
US cancer death rate drops by sharpest rate on record
US cancer death rate drops by sharpest rate on record
BioPharma Dive
cancer
Bristol-Myers Squibb
Yervoy
Merck
Keytruda
Flag link:

Pages